[go: up one dir, main page]

GB1360001A - Pharmaceutical compositions comprising substituted anilides - Google Patents

Pharmaceutical compositions comprising substituted anilides

Info

Publication number
GB1360001A
GB1360001A GB415470A GB415470A GB1360001A GB 1360001 A GB1360001 A GB 1360001A GB 415470 A GB415470 A GB 415470A GB 415470 A GB415470 A GB 415470A GB 1360001 A GB1360001 A GB 1360001A
Authority
GB
United Kingdom
Prior art keywords
bromine
iodine
polyfluoro
alkoxy
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB415470A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD International Holdings GmbH
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherico Ltd filed Critical Scherico Ltd
Priority to GB415470A priority Critical patent/GB1360001A/en
Priority to BE769148A priority patent/BE769148A/en
Publication of GB1360001A publication Critical patent/GB1360001A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1360001 Animal husbandry SCHERICO Ltd 16 June 1971 [16 March 1970] 4154/70 Heading A1M [Also in Divisions A5 and C2] Pregnant animals are treated with an androgenic active substituted anilide shortly before and/or during the period of Letal genital formation whereby litters produced consist solely of females and hermaphrodites, the said substituted anilide being of the general formula: or a pharmaceutically acceptable salt thereof wherein R represents a C 1-5 alkyl group of which carbon atoms at least one in secondary or tertiary; R' represents hydrogen or a C 1-6 alkyl group; B represents sulphur or oxygen; Y represents hydrogen, C 1-6 alkyl, halogen, nitro, carboxy (which may be esterified with a C 1-6 alkanol), hydroxy, C 1-6 alkoxy, C 1-6 alkanoyloxy, polyfluoro-C 1-6 alkoxy, polyfluoro-C 1-6 alkyl, trifluoromethylthio, trifluoromethylsulphoxy, trifluoromethylsulphonyl or C 1-6 alkanoyl; X represents iodine, trifluoromethyl, chlorine, bromine or iodine except a compound wherein B represents oxygen, R and R' are as defined above, and of X and Y, Y represents bromine, iodine, nitro, carboxy (which may be esterified with a C 1-6 alkanol), hydroxy, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, polyfluoro-C 1-6 alkoxy, trifluoromethylthio, trifluoromethylsulphoxy trifluoromethylsulphonyl or polyfluoro-C 1-6 -alkyl other than trifluoromethyl and X represents nitro, iodine, trifluoromethyl or bromine (X and Y not being both bromine); or Y represents trifluoromethyl and X represents iodine, bromine, or when R contains 6-8 carbon atoms of which at least two are secondary or tertiary ones, then X may also represent nitro. The substituted anilide may be administered in the form of a composition suitable for oral or parenteral administration and may be incorporated in an animal feedstock or feed-supplement.
GB415470A 1971-06-16 1971-06-16 Pharmaceutical compositions comprising substituted anilides Expired GB1360001A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB415470A GB1360001A (en) 1971-06-16 1971-06-16 Pharmaceutical compositions comprising substituted anilides
BE769148A BE769148A (en) 1971-06-16 1971-06-28 NEW THERAPEUTICALLY ACTIVE SUBSTITUTE ANILIDES AND THEIR MANUFACTURING PROCESSES.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB415470A GB1360001A (en) 1971-06-16 1971-06-16 Pharmaceutical compositions comprising substituted anilides
BE769148A BE769148A (en) 1971-06-16 1971-06-28 NEW THERAPEUTICALLY ACTIVE SUBSTITUTE ANILIDES AND THEIR MANUFACTURING PROCESSES.

Publications (1)

Publication Number Publication Date
GB1360001A true GB1360001A (en) 1974-07-17

Family

ID=25656912

Family Applications (1)

Application Number Title Priority Date Filing Date
GB415470A Expired GB1360001A (en) 1971-06-16 1971-06-16 Pharmaceutical compositions comprising substituted anilides

Country Status (2)

Country Link
BE (1) BE769148A (en)
GB (1) GB1360001A (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663353A (en) * 1979-03-06 1987-05-05 The United States Of America As Represented By The Secretary Of Agriculture Antibacterial fatty anilides
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en) * 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7022870B2 (en) 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7547728B2 (en) 2001-12-06 2009-06-16 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7776921B2 (en) 2002-02-07 2010-08-17 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with SARMS
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
CN103408447A (en) * 2013-07-01 2013-11-27 昆山三友医药原料有限公司 Process for synthesizing flutamide
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US9150501B2 (en) 2007-09-11 2015-10-06 Gtx, Inc. Solid forms of selective androgen receptor modulators
US9604916B2 (en) 2012-07-13 2017-03-28 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10849873B2 (en) 2012-07-13 2020-12-01 Oncternal Therapeutics, Inc Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663353A (en) * 1979-03-06 1987-05-05 The United States Of America As Represented By The Secretary Of Agriculture Antibacterial fatty anilides
US7041844B2 (en) 1996-11-27 2006-05-09 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6482861B2 (en) 1996-11-27 2002-11-19 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7129377B2 (en) 1996-11-27 2006-10-31 University Of Tennessee Research Foundation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en) * 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US9493403B2 (en) 2000-08-24 2016-11-15 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7547728B2 (en) 2001-12-06 2009-06-16 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7776921B2 (en) 2002-02-07 2010-08-17 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with SARMS
US8088828B2 (en) 2002-02-07 2012-01-03 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with SARMS
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7022870B2 (en) 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US8669286B2 (en) 2004-06-07 2014-03-11 University Of Tennessee Research Foundation SARMs and method of use thereof
US10662148B2 (en) 2004-06-07 2020-05-26 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US10053418B2 (en) 2004-06-07 2018-08-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9278914B2 (en) 2004-06-07 2016-03-08 University Of Tennessee Research Foundation SARMs and method of use thereof
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US8846756B2 (en) 2006-08-24 2014-09-30 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10300037B2 (en) 2006-08-24 2019-05-28 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US8426465B2 (en) 2006-08-24 2013-04-23 University Of Tennesse Research Foundation Substituted acylanilides and methods of use thereof
US9150501B2 (en) 2007-09-11 2015-10-06 Gtx, Inc. Solid forms of selective androgen receptor modulators
US12053448B2 (en) 2007-09-11 2024-08-06 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US11090283B2 (en) 2007-09-11 2021-08-17 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10849873B2 (en) 2012-07-13 2020-12-01 Oncternal Therapeutics, Inc Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy
US9604916B2 (en) 2012-07-13 2017-03-28 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US12115146B2 (en) 2012-07-13 2024-10-15 University Of Tennessee Research Foundation Treatment of skeletal-related events for breast cancer patients
CN103408447A (en) * 2013-07-01 2013-11-27 昆山三友医药原料有限公司 Process for synthesizing flutamide

Also Published As

Publication number Publication date
BE769148A (en) 1971-12-28

Similar Documents

Publication Publication Date Title
GB1360001A (en) Pharmaceutical compositions comprising substituted anilides
HU9400495D0 (en) Peptides having growth hormone releasing activity
ES8609279A1 (en) A PROCEDURE FOR THE PREPARATION OF NEW DERIVATIVES OF 1,2,3-TRIAZOLE.
ES485188A1 (en) Diphenylbutyl-piperzinecarboxamides
ES8403897A1 (en) 3-Aminoquinuclidin derivatives, process for their preparation and their use as therapeutical agents.
KR880006993A (en) Animal Breeding Composition Containing Beta-Adrenaline
ES312813A1 (en) Certain 6-substituted-imidazo[2, 1-b] thiazole compounds
ES8502099A1 (en) Derivatives of dihydrodibenzocycloheptylidene-ethylamine.
FR2547503B1 (en) NEW SOLVENT-AUXILIARY PENETRATION SYSTEM FOR THE ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE AGENTS BY PERCUTANEOUS ADMINISTRATION
GB1086192A (en) Phenylcyclopropane derivatives
ES427079A1 (en) Phenothiazine derivatives, compositions thereof and methods of preparation thereof
GB1250208A (en)
DE3068249D1 (en) Compositions including mercaptoorganopolysiloxanes, aliphatically unsaturated polydiorganosiloxanes and carboxylic acid salts of metals
GB1361407A (en) Substituted anilides
DE58903919D1 (en) Propanolaminderivate.
GB1437906A (en) Compositions for and method of promoting animal growth
JPS57129654A (en) Feed for domestic animals
GB1191016A (en) Iodinated Carboxyacylamino-Benzoic Acids
GB1505525A (en) Pyridopyrimidines
ES8606240A1 (en) 3-Substituted hydroxypentanedioic acids, -hemiesters or -anhydrides.
Laster et al. A note on the effect of ram to ewe ratio on reproductive performance of synchronized ewes
GB1042299A (en) Quinazoline derivatives
GB1344817A (en) Feed compositions and methods of use
JPS54151133A (en) Antitumorigenic agent
GB1509778A (en) Pharmaceutical composition and dosage units thereof

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PE20 Patent expired after termination of 20 years